Hong Kong PR

Naoris is Spearheading the First Decentralized Post-Quantum Infrastructure for Web2, Web3 & Web 4WELLINGTON, FL, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, the first in production quantum-resistant blockchain and cybersecurity mesh architecture, has announced its upcoming TGE for July 31, 2025, marking a key milestone in the rollout of a new foundational security layer for the internet, designed to protect both Web3 and Web2 ecosystems from quantum and traditional threats. The $NAORIS token will launch for trading on July 31 at 12:00PM UTC / 08:00AM ET. At TGE, the initial circulating supply will be 599.260,000 NAORIS tokens, with a fully diluted valuation (FDV) of $500M FDV. The token will be available for trading on Binance Alpha, Binance Perps, and Gate.io with additional exchange listings to be confirmed. For the latest details, visit the Naoris Protocol website on July 31.In terms of utility, the $NAORIS token powers a machine-driven trust economy, enabling real-time, quantum-resistant security validations across both Web3 and traditional Web2 infrastructures. Embedded at the Sub-Zero layer within a Decentralized Trust Mesh, $NAORIS powers autonomous device-to-device security challenges that trigger token swaps per block, ensuring continuous, automated trust without human input. Each node earns influence and rewards based on its trust score, creating a dynamic consensus system rooted in behavior and reliability. Token holders can stake to secure the network and participate in governance, aligning incentives with long-term protocol resilience.The announcement comes just weeks after Naoris raised $3 million in a strategic funding round led by Mason Labs, with participation from Frekaz Group, Level One Robotics and Tradecraft Capital.The $NAORIS token is the core utility asset powering this infrastructure, enabling access to security services, governance and incentives for network participants. As the lifeblood of the Naoris Protocol, $NAORIS serves as the cyber-trust primitive that drives decentralized security infrastructure across blockchains, enterprises and IoT ecosystems.Operating at the Sub-Zero Layer, beneath L0 to L2 blockchains, Naoris Protocol provides the trust and security fabric for decentralized applications and existing internet infrastructure. It integrates directly with EVM-compatible blockchains without requiring hard forks and extends protection to blockchain transactions, physical infrastructure, including enterprise systems, cloud platforms, IoT devices, validators, bridges and decentralized exchanges. Naoris Protocol’s Post-Quantum technology is aligned with NIST, NATO and ETSI post-quantum standards – the US Government has mandated that all digital systems transition to post-quantum cryptographic standards by 2030, with legacy algorithms fully phased out by 2035.“At Naoris, we firmly believe that blockchains cannot retrofit their way to post-quantum security, they must be built into the infrastructure from the ground up,” said Naoris CEO and Founder David Carvalho. “Our TGE helps us move closer to delivering the next standard in cyber-resilient infrastructure,ensuring global systems remain secure in the post-quantum era.”Naoris’ architecture combines Post-Quantum Cryptography, Decentralized Proof-of-Security (dPoSec) consensus, and Swarm AI to secure blockchain transactions and web infrastructure against quantum computing risks. Key features include:Quantum-Secure Blockchain Transactions: Enhances EVM blockchains against quantum threats without network disruptions.Trusted Web3 Infrastructure: Immutable, real-time mesh network secures nodes, validators, bridges, and DEXs.Distributed Web2 Security: Converts all devices into validator nodes, forming a self-healing network without single points of failure.Since launching its testnet in January, Naoris Protocol has recorded significant growth, with over 100 million post-quantum transactions processed, over 3.3 million wallets onboarded, over 1M security nodes and over 475 million cyber threats mitigated as well as 31 active projects under development across sectors such as finance, telecom, energy, defense, and IoT.Alongside CEO and Founder David Carvalho, Naoris Protocol is guided by a leadership team with deep expertise across cybersecurity, defense, and blockchain verticals, bringing together a diverse range of global experience. The team includes David Holtzman, former CTO of IBM and a key architect of the DNS protocol; Ahmed Réda Chami, Ambassador of Morocco to the European Union and former CEO of Microsoft North Africa; Mick Mulvaney, former White House Chief of Staff; and Inge Kampenes, retired Major General and former Chief of the Norwegian Armed Forces Cyber Defence. Their combined backgrounds reflect the protocol’s focus on building secure, scalable infrastructure for both Web3 and traditional systems.To learn more about Naoris Protocol, users can visit https://www.naorisprotocol.com/ About Naoris ProtocolNaoris Protocol is the world’s first Decentralized Post-Quantum Infrastructure, built to secure both Web3 and Web2 against traditional and quantum threats. Operating beneath blockchain layers 0 to 3 as a Sub-Zero Layer, it integrates with existing EVM chains, nodes, bridges, dApps, enterprise systems, and IoT devices without requiring hard forks.Media Contact: sharon@babslabs.io  Disclaimer: All product and company names herein may be trademarks of their registered owners.  The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Copyright 2025 ACN Newswire via SeaPRwire.com.

ANKARA, Turkey, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC®) in Toronto.This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20).The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease.No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%).Abidin Gülmüs, Chairman of GEN, stated:"We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease."Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added:"With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease."About SUL-238SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's "powerhouse." It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications.About GEN:Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments.About Sulfateq:Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health.For more information:www.genilac.com.trwww.sulfateqbv.comContact InformationBulutay GünesSr. Head of Corporate Brandb.gunes@genilac.comAli KetenciogluInvestor Relations Managera.ketencioglu@genilac.comKees van der GraafSulfateq CEOinfo@sulfateqbv.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - July 25, Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, stock code: 1788.HK), a company of Guotai Haitong Group, is pleased to announce that while actively saving energy and reducing emissions，it has successfully offset its Scope 1 and Scope 2 carbon emissions totaling 609.29 tons of carbon dioxide equivalent for the year 2024 by subscribing to the carbon credits issued under the international Verified Carbon Standard (VCS). This marks the third consecutive year that GTJAI has achieved “carbon neutrality” at the operational level, demonstrating the Company's leading practice and commitment to green operation.The carbon credits come from “Guoluo Grassland Sustainable Management Project” located in Guoluo Tibetan Autonomous Prefecture, Qinghai Province, China. It is dedicated to the restoration of degraded grassland ecosystems, based on the holistic nature of the ecosystems, in line with the concept of ecological civilization construction, and to effectively respond to the challenges of climate change. The project is also the first grassland carbon project in China receiving both VCS certification and the Climate, Community and Biodiversity Standards (CCB) - CCB-Biodiversity Gold Level certification.In recent years, GTJAI has been continuously reducing its operational carbon footprint through systematic energy saving and emission reduction initiatives, which is the core support for the achievement of “carbon neutrality”, including vigorously implementing energy-saving renovation of office space, deepening digitalization and paperless transformation, and implementing stringent waste management (100% safe recycling of hazardous waste by 2024). Solid internal emission reduction efforts, combined with carbon offsetting through high-quality carbon credits, enabled the Company to achieve “carbon neutrality” at the operational level.Adhering to the core philosophy of “finance for the country, finance for the people, finance for the good”, GTJAI has always placed sustainable development at the core of its corporate strategy. The Company is committed to supporting the real economy through financial services while facilitating the green transformation of its corporate clients. In 2024, the Company successfully completed 90 sustainable finance projects covering green bonds, sustainable bonds and green sector IPOs with a total issuance volume of HK$179.8 billion, significantly broadening the financing pipeline for the green industry. Meanwhile, the private equity sector is actively engaged in the sustainability sector, with more than half of its investments focusing on ESG-related industries.Looking ahead, GTJAI will deepen the level of ESG governance, fully integrate ESG factors into its operations and management processes, further leverage its professional strengths and enhance the level of green financial services capabilities. Through innovative products and services, GTJAI will proactively contribute to the realization of the country's “dual carbon” goal and promote the high-quality development of the economy and society.About GTJAIGuotai Junan International (“GTJAI”, Stock Code: 1788.HK), a company of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes brokerage, corporate finance, asset management, loans and financing, financial products, which cover three dimensions including individual finance (wealth management), institutional finance (institutional investor services and corporate finance) and investment management. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH; 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月29日 - (亞太商訊 via SeaPRwire.com) - 2025年7月25日，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK）欣然宣布，公司在積極節能减排的同時，通過認購符合國際核證碳標準（Verified Carbon Standard, VCS）的碳信用産品，成功抵消其2024年度範圍1及範圍2碳排放共計609.29噸二氧化碳當量。這標志著國泰君安國際連續第三年實現營運層面「碳中和」，彰顯了公司在綠色營運方面的領先實踐與承諾。公司本次認購碳信用産品來自于位于中國青海省果洛藏族自治州的「果洛草原可持續管理項目」，該項目致力于修復退化草地生態系統，立足生態系統整體性，契合生態文明建設理念，有效應對氣候變化挑戰。項目亦開創性地成爲中國首個獲得「雙認證」的草原碳匯項目，即VCS認證及氣候、社區和生物多樣性標準（Climate, Community and Biodiversity Standards, CCB）--生物多樣性黃金級別（CCB-Biodiversity Gold Level）認證。近年來，國泰君安國際自身通過系統性節能减排舉措持續降低營運碳足迹，爲連續實現「碳中和」提供核心支撑，舉措包括：大力推行辦公空間節能改造、深化數字化與無紙化轉型，以及實施嚴格的廢弃物管理（2024年有害廢弃物實現100%安全回收）。持之以恒的內部减排努力，結合高質量的碳信用産品抵消，共同夯實了公司營運層面「碳中和」的成果。秉持「金融報國、金融爲民、金融向善」的核心理念，國泰君安國際始終將可持續發展置于企業戰略的核心位置。公司致力于通過金融服務支持實體經濟，同時促進其企業客戶的綠色轉型。2024年，公司成功完成90個可持續金融項目，涵蓋綠色債券、可持續債券及綠色行業IPO，發行總量高達1,798億港元，顯著拓寬了綠色産業的融資渠道。同時，私募股權板塊積極布局可持續領域，過半數投資集中于ESG相關行業。展望未來，國泰君安國際將不斷深化ESG管治，將ESG因素全面融入運營與管理流程，進一步發揮專業優勢，提升綠色金融服務能級，通過創新産品與服務，積極助力國家「雙碳」目標實現，促進經濟社會高質量發展。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）, 是中國證券公司國際化的先行者和引領者，公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地，幷在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高品質、多元化的綜合性金融服務，核心業務包括經紀、企業融資、資産管理、貸款及融資與金融産品等，業務覆蓋個人金融（財富管理）、機構金融（機構投資者服務與企業融資服務）與投資管理三大維度。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球84%同業。公司控股股東國泰海通證券（股票代號：601211.SH/ 2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年7月28日 - (亞太商訊 via SeaPRwire.com) - 小黃鴨德盈控股國際有限公司（及其下屬公司合稱爲「小黃鴨德盈」或「集團」，股份代號：2250）公佈截至2025年6月30日止六個月（「期内」或「上半年」）盈利預告。期內，受益於集團角色授權業務的授權金收入顯著增長、設計諮詢服務費增加，以及電子商務及其他業務收入因持續於電商平台開展推廣工作而擴展等，預期集團整體業績改善。就集團上半年未經審核綜合管理賬目所作的初步評估（不包括合約資産、金融資産减值及公允值變動），預期小黃鴨德盈期內收入較上年的5,992萬港元同比大幅增長不低於30%。同時，經營虧損亦較上年大幅收窄不少於30%。小黃鴨德盈近年持續以創新驅動IP生態發展及系統協同，透過「IP+全産業鏈」的前瞻性布局，推動集團業務發展和全球化布局加速。未來，小黃鴨德盈將繼續創新商業模式，強化IP生態系統的協同效應，致力實現品牌價值與商業價值的長期穩健發展與共贏成長。關於小黃鴨德盈控股國際有限公司小黃鴨德盈控股國際有限公司是一家主要從事角色知識産權業務的投資控股公司。集團自 2005 年創立明星 IP「B.Duck 小黃鴨」以來，在 IP 各類授權及運營上擁有豐富經驗。集團著力於 IP 實景文旅、遊戲文娛、商品零售、跨境出海等業務增長點，實現IP授權、商品企劃、供應鏈、銷售渠道等業務板塊的優化整合，小黃鴨德盈不斷深化 IP 商業化生態圈建設，致力打造 B.Duck 成爲「全球快樂符號」，推動「Make A Playful World」的使命落地。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年7月28日 - (亞太商訊 via SeaPRwire.com) - 日本東京證券交易所掛牌企業 Quantum Solutions Co., Ltd. （東京證券交易所上市編號：2338）及其關聯公司（「Quantum Solutions集團」或「Quantum Solutions」）今日進一步公布集團在數字資產領域的戰略部署，並與亞洲知名數字資產科技公司 TDX Strategies Ltd 簽署業務合作協議。雙方將於比特幣交易執行、資產託管、結構化產品設計以及市場風險管理等方面展開全面合作，為 Quantum Solutions 的比特幣儲備計劃提供一站式技術與服務支持。Quantum Solutions 早前已公布，將於未來12個月內逐步建倉最多3,000枚比特幣，以對沖通脹風險、優化資產結構並提升財務系統的靈活性。本次與 TDX Strategies 的合作，標誌著相關業務從資本層面正式邁入系統化執行階段，合作框架的落地有望全面強化Quantum Solutions於數字資產運作方面的專業能力與風控保障。TDX Strategies 是一家專門從事數字結構化產品交易服務的科技型企業，在英屬處女群島（BVI）合法持有投資交易與營運許可。該公司擁有豐富的區塊鏈資產操作經驗與跨市場機構資源網絡，並與多家亞洲家族辦公室、資產管理機構及企業建立了長期合作。根據本次合作，Quantum Solutions  同意於未來24個月內非獨家形式優先考慮訂閱TDX 提供的加密貨幣服務、，以保障儲備業務的靈活性與穩定性。根據協議，TDX Strategies 將為 Quantum Solutions 的比特幣業務提供多層次支持，包括：協助構建比特幣交易與執行機制，以實現不同市場條件下的最優採購策略；建立符合企業級標準的冷／熱錢包管理系統與多重簽名安全架構，保障數字資產的託管與操作安全；根據持倉比特幣設計具備本金保障與收益增值潛力的結構化產品，提升資產使用效率；同時亦將於營運、技術、風險敞口控管、市場波動應對等領域提供持續的技術諮詢與策略建議。TDX Strategies 為一間科創型數字資產公司，在結構化金融工具、機構化交易系統、跨鏈資產解決方案方面具備實操經驗，技術團隊專長橫跨區塊鏈應用與傳統風控體系，於亞洲加密金融圈建立穩固聲譽。值得一提的是，TDX 屬 Quantum Solutions 的戰略合作方，美國著名財經媒體 福布斯Forbes Media LLC幕後東主任德章先生集團旗下。任德章先生同時亦為 Integrated Asset Management (Asia) Limited 的全資擁有人。該機構早前已向 Quantum Solutions 集團 提供 1,000 萬美元貸款，用以啟動比特幣儲備計劃的首階段資金投入。作為國際知名投資人，任先生不僅出資推動公司進軍數字資產領域，亦開放其科技資產平台 TDX Strategies 的應用權限與專業團隊予Quantum Solutions採用，實現全方位支持。Quantum Solutions 表示，是次合作為公司數字資產業務建立起涵蓋資金來源、技術執行與合規管控的完整支撐體系，構成從資本動員到資產運營的閉環模式。此舉進一步體現公司將比特幣由「儲備性資產」升級為「戰略性資產」的財務策略轉型方向，並強化其於企業財務架構中的核心地位與潛在價值。未來，Quantum Solutions 與 TDX 將持續拓展合作範圍，探索更多場景應用，包括但不限於比特幣收益管理、穩定幣配置與跨鏈結構化產品設計，提升數字資產的靈活性與多元增值能力。本次合作不僅是數字資產業務的具體落實，更象徵 Quantum Solutions 正積極構建面向未來的財務戰略框架。隨著比特幣儲備計劃的持續推進，公司預期將加速建立具制度化、審計能力與市場反應效率的企業級數字資產儲備體系，為中長期資產安全與企業成長提供雙重保障。關於 Quantum SolutionsQuantum Solutions Co.,Ltd.（東京證券交易所：2338.T）是一家總部位於日本東京的高成長科技企業，專注於人工智能、大數據分析及區塊鏈相關技術的研發與應用。公司成立於2004年，並于東京證券交易所掛牌上市。Quantum Solutions 的核心業務涵蓋金融科技、醫療健康、智能製造等多個行業領域，致力於以技術驅動產業轉型。截至 2025 年 2 月 28 日，公司實現收入約470 万美元，擁有数項游戏类别的注册商标和技術專利。更多信息請訪問公司官網：https://www.quantum-s.co.jp/en/corporate前瞻性聲明本新聞稿包含根據公司目前可取得之資訊，以及對未來事件與預期所作的若干假設所形成的前瞻性聲明。此類聲明涉及各種風險與不確定性，包括但不限於政策變動、市場狀況、技術發展及監管因素，皆可能導致實際結果與此類聲明中所表達或暗示的結果出現重大差異。建議現有及潛在投資者審慎評估潛在風險，並避免對本新聞稿中所包含的任何前瞻性聲明寄予過高信賴。此類聲明僅適用於本新聞稿發佈之日，除法律另有規定外，公司並無義務因新資訊、未來事件或其他情況而更新或修正任何前瞻性聲明。如有進一步查詢，請聯絡：香港/國際：Mr. Steven TungEmail: steven.tung@quantum-s.co.jp日本：Ms. Linda PengEmail: linda.peng@quantum-s.co.jp Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年7月28日 - (亞太商訊 via SeaPRwire.com) - 7月24日，中國再保險（香港）股份有限公司[以下簡稱"中再壽險（香港）"]主辦的優質醫療-無界溝通-粵港澳大灣區醫療保險發展論壇在香港舉行，並聯合母公司中國人壽再保險有限責任公司（以下簡稱"中再壽險"）正式發佈首款大灣區跨境醫療創新產品方案（以下簡稱"產品方案"）。依託國家政策指引和專業技術賦能，該產品方案突破跨境商保結算、特藥智能理賠、醫療信息壁壘等關鍵節點，打造全週期的"港人北上"醫療保障方案，與香港本地產品形成錯位互補，推動大灣區醫療保障互聯互通領域取得突破性進展。國務院《粵港澳大灣區發展規劃綱要》指出"推動粵港澳三地優質醫療衛生資源互聯互通，支持粵港澳保險機構合作開發創新型跨境醫療保險產品"。本次發佈會積極響應建設"健康灣區"號召，發揮再保險平台和資源鏈接優勢，匯聚了來自香港壽險、財險、再保、再保經紀等公司領導以及醫療、製藥、投資等領域權威專家，聚焦粵港澳大灣區跨境醫療保險融合發展建言獻策。中再壽險（香港）行政總裁羅亞偉在大會致辭中表示，中再壽險（香港）以民族再保險企業的為民初心、服務國家戰略的堅定決心以及與行業和生態夥伴共贏發展的誠摯真心，破解痛點，研發大灣區跨境醫療創新產品，以期為居民跨境醫療帶來革命性便利，為"健康灣區"貢獻堅實力量。作為本次會議的重要議題，首款大灣區跨境醫療創新產品方案重磅發佈。中再壽險產品開發部總經理助理王明彥對於產品形態和核心優勢進行瞭解讀。中再壽險作為內地商業醫療險的領軍者，憑藉在醫療產品創新、"三醫聯動"領域的深厚積澱、海量數據優勢及領先的科技風控手段，精准洞察"港人北上"就醫需求與政策機遇，深度整合內地與香港醫療資源優勢，針對性研發出此跨境醫療解決方案。新產品主要聚焦香港本地中等收入人群及內地居港新移民，為其提供獨立、高性價比的內地住院醫療保障，並深度整合內地優質醫療資源與服務網絡，兜底大病風險，打通港人北上就醫關鍵節點，顯著提升服務體驗。後續也可以針對不同保司的需求，進行定制化方案設計，誠邀各位合作夥伴共同合作、共建灣區。在全場嘉賓的見證下，中再壽險（香港）、中銀人壽、中銀集團保險、太平人壽（香港）、太平保險（香港）和鎂信健康公司等相關負責人，共同發佈"服務國家戰略，共建健康灣區"倡議。這一標誌性時刻，宣告"保險+健康+醫療科技"融合創新模式落地香港國際金融中心。圓桌論壇環節中來自保險、醫療等各界嘉賓，聚焦產品創新攻堅、科技賦能升級、產業生態融合和政策研究等話題積極建言獻策。特別是針對大灣區醫療資源發展還需更加平衡、跨境醫療創新還需進一步樹立客戶信心、跨境融合的上下游執行標準還需進一步統一等關鍵問題展開討論，也為未來行業共同打造"灣區一小時健康生態圈"提供了攻堅方向。大會最後，中再壽險（香港）董事長李明在總結發言中表示，論壇在服務人民健康開啟跨境醫療創新里程碑、服務市場需求攜手共贏促進行業發展、拓展產業生態圈開放協同推動跨領域合作三個方面取得了超過預期的成果，進一步凝聚起各界共識。期待各位夥伴攜手同行，用專業與誠意澆灌"跨境醫療創新"種子，共同迎接粵港澳大灣區醫療健康碩果滿枝的明天。目前，中國再保險（集團）股份有限公司已成立粵港澳大灣區協同發展工作組，依託遍佈廣東全省分支機搆，以及中再資產（香港）、中再壽險（香港）兩個平台，錨定服務健康養老、實體經濟、新質生產力等重點方向。下一步，中再壽險（香港）將以跨境醫療保險為突破口，推動"港人北上"醫療、養老便利化；提升資產負債協同效能，支持內地與港澳保險機構開展保險產品跨境交易和跨境人民幣再保險業務；推動海外特藥保險等一批國內優秀保險方案"走出去"，為服務粵港澳大灣區戰略貢獻再保智慧和力量。 Copyright 2025 亞太商訊 via SeaPRwire.com.

上海，2025年7月28日 - (亞太商訊 via SeaPRwire.com) - 2025年7月26日，中信國際電訊集團有限公司（股份代號：1883）攜旗下澳門電訊（CTM）、中信國際電訊CPC、中企通信等多家子公司，連續第四年在中信集團的統一部署下亮相2025世界人工智能大會。中信國際電訊緊扣本屆大會「智能時代 同球共濟」主題，以中信集團「要出國、找中信，來中國、找中信」服務品牌為引領，聚焦「智鏈國際 服務全」戰略方向，全面展示在人工智能技術與大模型發展領域的前沿探索，呈現在推動企業智能化升級、加速數字經濟互聯互通、強化企業「走出去」與「引進來」雙循環支撐體系、以及推動AI技術與產業場景深度融合等多方面的創新實踐與突破性成果。中信國際電訊正持續發揮橋樑紐帶作用，深度參與全球科技生態建設，助力企業「走出去」 、「引進來」 ，為全球智能科技發展注入新動能。  「智慧中信 共創新可能」本屆大會，中信集團以「智慧中信 共創新可能」為主題重磅亮相，依託「科技-產業-金融」循環聯動的綜合優勢，集中呈現了在科技創新、新興產業、金融賦能及國際化等領域的AI前沿應用與行業解決方案。作為中信集團新消費板塊的關鍵組成部分，中信國際電訊重點參與了集團展區「科技創新」與「國際化」兩大主題區域的展示，充分發揮旗下子公司協同優勢，強化技術底座支撐、產業賦能和生態協同，全力釋放 AI 高質量發展動能，為數字中國建設及全球數字經濟互聯互通貢獻中信智慧和中信方案。與此同時，中信國際電訊還在展區現場開展多場「中信AI+實踐分享」互動演示，向業界生動呈現這些創新成果的實踐價值與應用潛力。 「智鏈」國際，服務全球，燃動高質量發展「新引擎」全球數字經濟迅猛發展，中信國際電訊作為中信集團國際化業務的重要支撐力量，積極踐行國家「人工智能+」與高水平對外開放戰略部署，致力構建全球互聯的數智生態體系，持續拓展「走出去」、「引進來」雙向通道，打造開放、互信、共贏的全球數字生態。為實現這一戰略目標，中信國際電訊已在全球五大洲部署了豐富資源，近170個網絡服務節點、21座雲平台、30+數據中心及3座全天候運營的安全運作中心（SOCs），構建起全球範圍內覆蓋廣泛、響應敏捷的數智雲網安服務。不僅「智鏈」央國企及中資企業的全球安全連接需求，並為眾多外資跨國機構提供敏捷可靠的本地化智能雲網安服務，成為連接國際與本土、產業與科技的關鍵橋樑。此外，中信國際電訊也進一步深化區域協同與屬地化運營能力。旗下子公司ACCLIVIS深耕東盟市場，積極推動AI、雲網安全等技術在醫療、製造等領域應用，為南向通道注入源源不斷的創新動能；在港澳及大灣區，澳門電訊（CTM）深度參與「智慧澳門」建設，聚焦助力澳門經濟適度多元發展，推動智慧政務、智慧校園、智慧轉型等領域，成功打造出AI+通信技術融合的區域協同項目，為區域高質量發展提供強有力的數智支撐。截至目前，中信國際電訊已累計賦能3000餘家中外企業跨境發展，服務全球超過4萬家本地客戶，其中包括200餘家世界500強企業，切實將「全球戰略」規劃圖轉化為實景圖，攜手合作夥伴，共築智能互聯的數字未來。科技引領，聚勢賦能，「智鏈」未來新篇章中信國際電訊不斷夯實技術創新根基，打造面向未來的企業級數字能力底座，構建全球互聯數字新生態。公司憑藉深厚的技術積累與創新研發體系，圍繞AI+大數據、AI+網絡、AI+大模型應用等核心方向，持續推出可規模化複製的落地方案。在AI數據治理領域，「AI Databank智數庫」數據智能平台深度融合大數據、AI、大語言模型（LLM）和生成式AI技術，構建統一數據平台，成功打破數據孤島，實現多業務系統數據的無縫整合，已在多行業中實現廣泛應用。憑藉其突破性的人工智能數據治理技術與前瞻的實用價值，AI Databank更是獲得了2025年「第50屆日內瓦國際發明展覽會銀獎」，這一國際權威認證彰顯了中信國際電訊在AI賽道科研與創新的優秀能力。在網絡服務領域，「AI智能加速包」通過優化網絡路由和節點，顯著提升跨國企業全球數據傳輸效率和穩定性，結合先進數智技術與GSMA Open Gateway國際標準，已成功應用於港澳智慧旅遊場景，獲得了「Open Gateway全球應用場景設計開發大賽三等獎」的殊榮。在智賦民生領域，中信國際電訊展示了澳門電訊「智慧城市」 方案及萬兆網絡基建發展。澳門電訊率先以F5G-A與5G-A雙擎技術為基座 ，實現千兆網絡澳門全域覆蓋，並建成澳門首個「萬兆小區」，打造更多智能應用場景，推動公共服務和城市管理的數字化轉型，塑造「科技以人為本」的可持續未來。項目斬獲多個國內國際一流獎項，彰顯「數字澳門」與「科技強國」的同頻共振。憑藉AI技術的全生命周期服務能力，中信國際電訊正在逐步建立起從底層基礎設施到上層應用的完整創新鏈條，為產業的數智轉型提供強有力支撐，助力企業在全球化進程中贏得競爭優勢。合規護航，數據強基，「智鏈」 可信數字世界技術創新推動企業邁向全球化新高度，但數據安全與合規風險亦隨之凸顯。中信國際電訊積極響應國家《數據安全法》、《個人信息保護法》，並對接歐盟GDPR、東南亞PDPA等國際標準，前瞻布局AI時代的數據安全與合規服務體系，重點解決跨境數據傳輸、信息存取保障及金融風控等關鍵挑戰，為構建「 智能可信「 的數字世界提供全棧式安全保障。智匯未來，中信國際電訊在「中信AI+實踐分享」環節，聚力分享多個融合「科技-產業-金融」三大領域的輕量化AI+應用項目，致力以數智技術服務全球企業。《AI賦能金融防欺詐項目》聚焦金融安全領域。在跨境交易中，金融防欺詐已成為保障交易安全的關鍵一環。中信國際電訊推出的「AI賦能金融防欺詐解決方案」通過多層次的身份驗證與實時交易監控，有效防止跨境交易中的欺詐行為，保障金融機構和用戶資產安全，展現數字金融領域創新實力。《智鏈｜安全重啟，精準智析》專註於新一代網絡安全防護體系的建設。中信國際電訊構建了全方位、多層次的智能安全防禦矩陣，AI Pentest智能滲透測試系統通過模擬攻擊與漏洞掃描，實現對潛在安全隱患的主動識別和修復，助力企業有效防範外部威脅與信息泄露風險；配合三個自建、自營、自管的AI-SOC智能安全運營中心，依託機器學習算法和大數據分析能力，整合AI大模型技術，提供實時威脅監測與自動化應對能力，為企業構建強韌的安全屏障；「AI安全圍欄」則覆蓋從終端到傳輸層的各關鍵節點，有效阻斷非法訪問、跨境數據泄露等安全風險。《智鏈｜從技術賦能到數據賦能》以數據治理與價值挖掘為核心。中信國際電訊通過創新專利技術、智能算法與大數據分析，協助企業實現安全高效的數據治理、跨系統整合及智能分析報告生成。同時賦能企業快速利用大模型技術，多元化小場景應用，處理數據收集、監測與合規報告。通過統一數據平台，以創新技術重塑企業級數據治理架構。面向未來，中信國際電訊將繼續以「鏈接」為本、以「智鏈」為要，依託中信集團的金融、科技與產業協同優勢，持續加大AI領域投入，推動更多「可用、可管、可信」的技術成果轉化落地，在智能時代的全球合作浪潮中，擔當中國企業高水平開放與科技出海的重要橋樑。相約H2館A308展區路漫漫其修遠兮，吾將上下而求索。面向數智時代的滾滾浪潮，科技創新是企業應變的核心引擎，更是國家發展的底氣。中信國際電訊正加快技術布局，以AI、大數據、雲計算、網絡安全等為支點，持續拓展「科技+」的全球版圖。我們期待與各方同仁攜手同行，智啟未來，共創共贏。「中信AI+實踐分享」詳情, 請參閱: https://mp.weixin.qq.com/s/svkprkpnnoC04gdsKZh9HA關於中信國際電訊集團有限公司（股份代號：1883）中信國際電訊集團有限公司於1997年在香港成立，並於2007年4月3日在香港聯合交易所上市。中信國際電訊作為亞太最大的國際電訊樞紐之一，為全球運營商客戶提供全面的國際電訊服務，並透過全資附屬公司Acclivis Technologies and Solutions Pte. Ltd.，在東南亞提供一站式跨區域企業服務。中信國際電訊全資附屬公司中信國際電訊（信息技術）有限公司（「CPC」）為全球跨國企業客戶和商業客戶提供一站式信息及通訊解決方案，CPC是亞太區跨國企業及商業客戶最可信賴的主要合作夥伴之一，同時透過附屬公司中企網絡通信技術有限公司，為中國內地大型企業及跨國商業客戶提供全方位ICT服務。中信國際電訊持有澳門電訊有限公司（「澳門電訊」）99%權益。澳門電訊是澳門主要的綜合電訊服務供貨商之一，亦是澳門唯一提供全面電訊和ICT服務的供應商，具市場領先地位，對澳門的持續發展舉足輕重。本集團在全球22個國家和地區設有分支機構，擁有約2,500位員工，全球網絡節點近170個、業務覆蓋達160個國家和地區，連接世界上600多家運營商，服務3,000多家跨國企業以及4萬餘家當地企業。中國中信集團有限公司為一家總部設於中國的大型綜合性跨國企業集團，是本公司的最終控股公司。如欲索取更多數據，請瀏覽以下網址：www.citictel.com。新聞垂詢：中信國際電訊李凱雯小姐電話：+852 3423 3168電郵：sylviali@citictel.com中信國際電訊CPC阮穎珊小姐電話：+852 2170 7536電郵：catherine.yuen@citictel-cpc.com Copyright 2025 亞太商訊 via SeaPRwire.com.

土耳其安卡拉，2025年7月29日 - (亞太商訊 via SeaPRwire.com) - GEN製藥公司（GENIL.IS）是土耳其領先的專業製藥公司，日前宣布其第一階段臨床試驗取得積極結果。該試驗旨在評估首創且新型的口服線粒體靶向候選藥物 SUL-238 在健康老年志願者中的安全性、耐受性以及藥代動力學（PK）表現。研究結果已在2025年阿茲海默症協會國際會議（AAIC®）上於多倫多公佈。本次第一階段臨床試驗為首個人體試驗，採用單次口服遞增劑量（SAD）設計，隨機、雙盲、安慰劑對照，共分為三個部分，納入了共計53名健康老年志願者。第一部分包括6個劑量組（口服劑量分別為50、100、250、500、1000和2000毫克，n=23）。第二部分中，研究了單劑1000毫克口服劑量在10名健康老年人的藥代動力學特徵。第二部分B評估了食物的影響，採用隨機、單劑2000毫克口服、雙處理、雙週期交叉設計（n=20）。試驗結果顯示，50至2000毫克的單次口服劑量 SUL-238 在受試者中均表現出良好的安全性和耐受性，同時具備良好的藥代動力學特徵，並能良好地滲透至腦脊液（CSF）。這些結果使得 SUL-238 成為治療包括阿茲海默症在內的神經退行性疾病的具前景的臨床開發候選藥物。未觀察到任何不良反應（AEs）限制劑量遞增，SUL-238組與安慰劑組的不良事件發生率相當，且所有不良事件均為輕度或中度。平均終末消除半衰期為0.86至3.80小時，達峰時間為0.50至1.39小時。在進食狀態下，血漿藥物最大濃度（Cmax）和血漿濃度-時間曲線下面積（AUC0-∞）分別下降了50%和60%。給藥後2小時和8小時腦脊液與血漿的濃度比例分別為21.1%（±6.6%）和74.2%（±46.0%）。GEN董事長 Abidin Gülmüş 表示：「這些令人鼓舞的首次人體試驗結果為我們帶來了極大信心，標誌著我們在應對阿茲海默症潛在生物機制方面邁出了重要一步。」GEN研發副總裁、醫學博士兼博士 Nadir Ulu 補充道：「在本次第一階段試驗中，SUL-238 展現出優異的安全性和藥代動力學特徵，結合扎實的臨床前數據，使其成為未來臨床開發的有力候選藥物，有望滿足包括阿茲海默症在內的神經退行性疾病領域亟待解決的臨床需求。」關於 SUL-238SUL-238 是一種首創的新型小分子藥物，其源自冬眠機制，靶向細胞的「能量工廠」——線粒體。該藥物通過激活線粒體複合體 I 和 IV 來支持線粒體的生物能量代謝，並已在神經退行性疾病、心血管疾病、腎臟疾病及衰老的囓齒動物模型中顯著改善線粒體功能。SUL-238 能穿越血腦屏障，並已在臨床前研究和第一階段試驗中完成了廣泛的安全性評估。GEN 獲得了 Sulfateq BV 授權，可將 SUL-238 應用於神經退行性疾病的治療開發。關於 GENGEN 成立於1998年，是土耳其領先的專業製藥公司，致力於在多個治療領域開發創新療法。GEN 擁有符合 GMP 認證標準的生產設施，生產高品質且具市場競爭力的藥品，並通過兩個專屬研發中心及研發投資推動原創藥物開發。關於 SulfateqSulfateq B.V. 是一家位於荷蘭的早期生物技術公司，致力於與學術界和產業研究中心開展戰略合作，以加速創新藥物的開發。該公司開發了一類新型小分子化合物——SUL 系列藥物，旨在維持線粒體健康功能。欲了解更多資訊:www.genilac.com.trwww.sulfateqbv.com聯絡資訊Bulutay Güneş企業品牌資深主管b.gunes@genilac.comAli Ketencioglu投資人關係經理a.ketencioglu@genilac.comKees van der GraafSulfateq 執行長info@sulfateqbv.com Copyright 2025 亞太商訊 via SeaPRwire.com.

SHENZHEN, CHINA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.About Product ZUNVEYLZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. As the second oral therapy approved by FDA for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better gastrointestinal safety profile to improve compliance of Alzheimer’s disease patients and therefore brings clinical benefits. Patent in regard to use of ZUNVEYL has already been granted in China.About Alzheimer’s DiseaseAlzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, and drug intolerance is one of the challenges in current treatment of Alzheimer’s disease. Tolerability affects therapy adherence, with data showing that 55% of Alzheimer’s disease patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among patient’s family, physicians, and caregivers[9]. Therefore, Alzheimer’s disease patients still have an urgent need for safer therapies.On 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”)  with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type. In accordance with the Agreement, the Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East region), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years (the “Initial Term”), it may be automatically renewed every five years upon the expiration of the Initial Term unless terminated by notice from either party.Around six months after obtaining the above rights of ZUNVEYL, the Group promptly submitted the NDA in China, demonstrating its efficient allocation of resources and robust capabilities in registration promotion. ZUNVEYL will further diversify the Group’s innovative drug product matrix and enhance the Group’s comprehensive competitiveness. The Product will synergize with the Group’s various central nervous system products including the innovative drug VALTOCO (diazepam nasal spray) and the original brand drug Deanxit (flupentixol and melitracen tablets) on sale and the innovative drug Y-3 for Injection under development in terms of expert network and market resources. Relying on the Group’s successful commercialization experience and compliant and efficient commercialization system, if ZUNVEYL is approved for marketing, it will bring a new drug option for the treatment of cognitive impairment in Chinese Alzheimer’s disease patients, meeting the clinical need for drugs of both efficacy and safety, improving disease diagnosis and treatment practices, thereby benefiting patients. The Product is expected to have a positive impact on the Group’s financial results.Reference:1. Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.00000000000118322. Safety profile of ZUNVEYL as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease- 3. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0034. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer's Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0045. Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-76. Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.7. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-200481038. Research Report on the Diagnosis and Treatment of Alzheimer’s Disease Patients in China (2020). Alzheimer's Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html9. Data on patient discontinuation as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease-About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.